The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review
文献类型：期刊论文
| 作者 | He, Libin2; Shen, Xiabo3; Liu, Yiyuan2; Gao, Lu2; Wu, Jiayi2; Yu, Chang1; Li, Guangliang3; Wang, Xiaojia3,4; Shao, Xiying3,4,5 |
| 刊名 | TRANSLATIONAL CANCER RESEARCH
 |
| 出版日期 | 2022-11-15 |
| ISSN号 | 2218-676X |
| 关键词 | Advanced human epidermal growth factor receptor 2-positive breast cancer (advanced HER2-positive breast cancer) apatinib case report |
| DOI | 10.21037/tcr-22-2483 |
| 通讯作者 | Shao, Xiying(shaoxy@zjcc.org.cn) |
| 英文摘要 | Background: Human epidermal growth factor receptor 2 (HER2)-targeted treatment has yielded a notable clinical benefit in patients with HER2-positive breast cancer. However, nearly 50% of patients still suffer disease progression due to resistance to HER2-targeted therapy. After the failure of macromolecular monoclonal antibodies (mAbs) therapy, we can choose small molecule tyrosine kinase inhibitors (TKIs) to reverse HER2 resistance. When small molecule TKIs resistance, we can use mAb combined with small molecule TKI, or antibody-drug conjugates (ADCs) to reverse HER2 resistance. However then due to the availability and price of ADCs, patients may not use them. Consequently, new therapeutic approaches are required to overcome HER2-targeted therapy resistance. Vascular endothelial growth factor and its receptors (VEGF/VEGFRs) promote tumor angiogenesis. They can also activate downstream signaling pathways to promote tumorigenesis. VEGFR is a key regulator of the tyrosine kinase signaling pathway and may be a potential target in HER2-positive breast cancer. Apatinib is a small molecule TKI that specifically binds to VEGFR2 and thus exerts an antitumor effect. Although there is no definite indication for apatinib in breast cancer, it has a good benefit in advanced gastric cancer.Case Description: The two patients we reported were both HER2-positive breast cancer who we followed for more than 10 years. After the failure of multi-line anti-HER2 treatment, apatinib combined with anti-HER2 treatment had PFS of 8.4 months and 10.6 months, respectively. One patient had grade 2 hand-foot syndrome. The other had grade 2 leukopenia and grade 2 thrombocytopenia, both of them improved after control. And the best response of them were PR and SD, respectively.Conclusions: Our cases demonstrate that, in HER2-positive breast cancer patients with HER2-targeted resistance, apatinib may be able to reverse HER2 resistance. These two cases suggest an alternative method for clinical HER2-targeted treatment of drug-resistant breast cancer patients and provide new insights for future research. |
| WOS关键词 | PHASE-II ; BEVACIZUMAB ; COMBINATION ; GROWTH ; HER2 ; ANGIOGENESIS ; TRASTUZUMAB ; MECHANISMS ; VEGFR2 |
| 资助项目 | Projects of Medical and Health Technology Science and Technology Program in Zhejiang ; [2016KYA046] ; [2015RCB005] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | AME PUBLISHING COMPANY |
| WOS记录号 | WOS:000889829800001 |
| 资助机构 | Projects of Medical and Health Technology Science and Technology Program in Zhejiang |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/131676]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Shao, Xiying |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pathol, Hangzhou, Peoples R China 2.Zhejiang Chinese Med Univ, Affiliated Coll 2, Hangzhou, Peoples R China 3.Canc Hosp Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China 4.Inst Basic Med & Canc IBMC, Chinese Acad Sci, Hangzhou, Peoples R China 5.Canc Hosp Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Breast Med Oncol, Hangzhou 310022, Peoples R China |
| 推荐引用方式 GB/T 7714 | He, Libin,Shen, Xiabo,Liu, Yiyuan,et al. The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review[J]. TRANSLATIONAL CANCER RESEARCH,2022. |
| APA | He, Libin.,Shen, Xiabo.,Liu, Yiyuan.,Gao, Lu.,Wu, Jiayi.,...&Shao, Xiying.(2022).The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review.TRANSLATIONAL CANCER RESEARCH. |
| MLA | He, Libin,et al."The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review".TRANSLATIONAL CANCER RESEARCH (2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。